PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
Francesco Passiglia(University of Palermo), Antonio Russo(University of Palermo), Clara Natoli(Kliniken Essen-Mitte), Viviana Bazan(University of Palermo), Giuseppe Cicero(University of Palermo), Antonio Galvano(University of Palermo), Christian Rolfo(Icahn School of Medicine at Mount Sinai), Angela Listì(University of Palermo), Daniele Santini(Policlinico Umberto I), Sérgio Rizzo(University of Palermo), Giuseppe Bronte(University of Ferrara)
Cited by 166
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
|New England Journal of Medicine|2009|2.4k
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
|Journal of Thoracic Oncology|2021|642